Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2003 Jun;5(3):326-30.

Technology evaluation: PK1, Pfizer/Cancer Research UK.

Author information

  • 1Department of Urology, Niigata University School of Medicine, Niigata University, Asahimachi 1, Niigata 951-8510, Japan. vbilim@med.niigata-u.ac.jp

Abstract

Pfizer (formerly Pharmacia) is collaborating with Cancer Research UK in developing PK1 (FCE-28068) for the potential treatment of various cancers. PK1 is an N-(2-hydroxypropyl) methacrylamide (HPMA) co-polymer-doxorubicin conjugate, attached by a peptide linker, which is currently undergoing phase II trials for breast, non-small-cell lung and colon cancers.

PMID:
12870445
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk